These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36335)

  • 21. [Noncompliance--a typical problem in psychiatric patients. Individual, social and illness-specific factors].
    Hartung HD
    Fortschr Med; 1998 Jan; 116(3):28-30. PubMed ID: 9522542
    [No Abstract]   [Full Text] [Related]  

  • 22. Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia.
    Mancevski B; Keilp J; Kurzon M; Berman RM; Ortakov V; Harkavy-Friedman J; Rosoklija G; Dwork AJ
    Psychopathology; 2007; 40(2):83-92. PubMed ID: 17215594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Negative symptoms of schizophrenia: a problem that will not go away.
    Stahl SM; Buckley PF
    Acta Psychiatr Scand; 2007 Jan; 115(1):4-11. PubMed ID: 17201860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intensity of psychotic symptoms and selected demographic data as predictors of effectiveness of psychotherapy of schizophrenic patients in a day-hospital treatment].
    Kamiński R; Lisiecka A
    Psychiatr Pol; 2002; 36(2):211-23. PubMed ID: 12043040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Negative symptom assessment of chronic schizophrenia patients.
    Raskin A; Pelchat R; Sood R; Alphs LD; Levine J
    Schizophr Bull; 1993; 19(3):627-35. PubMed ID: 8235463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 28. [Life planning and psychosis--treatment of schizophrenia in unusual circumstances].
    Jung S
    Psychiatr Prax; 1996 May; 23(3):144-5. PubMed ID: 8711008
    [No Abstract]   [Full Text] [Related]  

  • 29. Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia.
    Barnes TR; Liddle PF; Curson DA; Patel M
    Br J Psychiatry Suppl; 1989 Nov; (7):99-103. PubMed ID: 2575915
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.
    Janssen B; Gaebel W; Haerter M; Komaharadi F; Lindel B; Weinmann S
    Psychopharmacology (Berl); 2006 Aug; 187(2):229-36. PubMed ID: 16710714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacoepidemiology of treatment-refractory schizophrenia.
    Collins EJ; Hogan TP; Awad AG
    Can J Psychiatry; 1992 Apr; 37(3):192-5. PubMed ID: 1350502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of antipsychotic drugs and symptomatology on perceptual asymmetry in schizophrenia.
    Carr V; Wale J
    J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1531-7. PubMed ID: 2906089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topiramate for refractory schizophrenia.
    Millson RC; Owen JA; Lorberg GW; Tackaberry L
    Am J Psychiatry; 2002 Apr; 159(4):675. PubMed ID: 11925318
    [No Abstract]   [Full Text] [Related]  

  • 34. Current outcome in schizophrenia: women vs men.
    Seeman MV
    Acta Psychiatr Scand; 1986 Jun; 73(6):609-17. PubMed ID: 2875610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depressive symptoms and schizophrenia a psychopharmacological approach.
    Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G
    Encephale; 1995; 21(5):555-8. PubMed ID: 8529564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defining treatment refractoriness in schizophrenia.
    Brenner HD; Dencker SJ; Goldstein MJ; Hubbard JW; Keegan DL; Kruger G; Kulhanek F; Liberman RP; Malm U; Midha KK
    Schizophr Bull; 1990; 16(4):551-61. PubMed ID: 1981813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life of schizophrenic patients on medications and implications for new drug trials.
    Awad AG
    Hosp Community Psychiatry; 1992 Mar; 43(3):262-5. PubMed ID: 1348238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients.
    van Berckel BN; Hijman R; van der Linden JA; Westenberg HG; van Ree JM; Kahn RS
    Biol Psychiatry; 1996 Dec; 40(12):1298-300. PubMed ID: 8959296
    [No Abstract]   [Full Text] [Related]  

  • 39. Do negative symptoms respond to pharmacological treatment?
    Kane JM; Mayerhoff D
    Br J Psychiatry Suppl; 1989 Nov; (7):115-8. PubMed ID: 2575914
    [No Abstract]   [Full Text] [Related]  

  • 40. A comparison of patients who refuse and consent to neuroleptic treatment.
    Marder SR; Mebane A; Chien CP; Winslade WJ; Swann E; Van Putten T
    Am J Psychiatry; 1983 Apr; 140(4):470-2. PubMed ID: 6132559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.